Overexpression of cyclin D1 correlates with sensitivity to cisplatin in squamous cell carcinoma cell lines of the head and neck

Acta Oto-Laryngologica

Volumn 124, Issue 7, 2004, Pages 851-857

  Åkervall, Jan ^a,b   Kurnit, David M ^c   Adams, Meredith ^a   Zhu, Shaobo ^a,d   Fisher, Susan G ^e   Bradford, Carol R ^a   Carey, Thomas E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

Chemosensitivity; Cyclin D1; Gene expression; Head and neck; Squamous cell carcinoma

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BIOLOGICAL MARKER; CISPLATIN; CYCLIN D1;

ARTICLE; BIOASSAY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER STAGING; CHEMOSENSITIVITY; CHROMOSOME 18Q; CYCLIN D1 GENE; DIFFERENTIAL POLYMERASE CHAIN REACTION; DNA PROBE; DRUG RESPONSE; DRUG SENSITIVITY; GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IC 50; ID 50; IN VITRO STUDY; MICROSATELLITE MARKER; MTT ASSAY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CHROMOSOMES, HUMAN, PAIR 18; CISPLATIN; DISEASE-FREE SURVIVAL; DNA PROBES; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-1; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSATELLITE REPEATS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 4644281290     PISSN: 00016489     EISSN: None     Source Type: Journal    
DOI: 10.1080/00016480410017323     Document Type: Article

References (25)

1. Weaver A, Fleming S, Ensley J, Kish J, Jacobs J, Crissman J, et al. Superior clinical response and survival rates with initial bolus of Cisplatin and 120 hours infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancer. Am J Surg 1984; 148: 525-9.
2. Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction chemotherapy with 120-hours 5-FU infusion and Cisplatin. Cancer 1985; 55: 1123-8.
3. Wolf GT, Hong WK, Fisher SG. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1988; 324: 1685-90.
4. Pignon J, Bourhis J, Domenge C, Designe L. Chemotherapy added to loco-regional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000; 355: 949-55.
5. Akervall J, Brun E, Dictor M, Wennerberg J. Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck. Acta Oncol 2001; 40: 505-12.
6. Bradford CR, Zhu S, Wolf GT, Poore J, Fisher SG, Beals T, et al. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Cancer Study Group. Otolaryngol Head Neck Surg 1995; 113: 408-12.
7. Bradford C, Zhu S, Johnson G, Carey T. p53 mutation and cisplatin sensitivity in laryngeal carcinoma cell lines. Proc Am Assoc Cancer Res 2000; 41: 690.
8. Temam S, Flahault A, Périé S, Monceaux G, Coulet F, Callard P, et al. p53 gene status as a predictor of tumour response to induction chemotherapy of patients with loco-regionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2000; 18: 385-94.
9. Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier A, Souss T, et al. p53 alterations predict tumor response to neo-adjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 2000; 18: 1463-73.
10. Imoto M, Doki Y, Jiang W, Man E, Weinstein I. Effects of cyclin D1 overexpression on G1 progression related events. Exp Cell Res 1997; 236: 173-80.
11. La Thangue N. DRTF1/E2F: an expanding family of hetero dimeric transcription factors implicated in cell cycle control. Trends Biochem Sci 1994; 19: 108-14.
12. Akervall J. Prognostic factors in squamous cell carcinoma of the head and neck [Medical Thesis]. Lund, Sweden: Lund University; 1998.
13. Jiang W, Kahn S, Zhang Y, Cacae A, Infante A, Doi S, et al. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 1993; 8: 3447-57.
14. Hinds P, Dowdy S, Eaton E, Arnold A, Weinberg R. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci U S A 1994; 91: 709-13.
15. Akervall J, Brun E, Michalides R, Dictor M, Balm A, Wennerberg J. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 over expression. Cancer 1997; 79: 380-9.
16. Loehrer P, Einhorn L. Cisplatin. Ann Intern Med 1984; 100: 704-13.
17. Hochhauser D. Modulation of chemosensitivity through altered expression of cell cycle regulatory genes in cancer. Anticancer Drugs 1997; 8: 903-10.
18. Higuchi R, Fockler C, Dollinger G, Watson R. Kinetic PCR: real time monitoring of DNA amplification reactions. Bio/Technology 1993; 11: 1026-30.
19. Heid C, Stevens J, Livak K, Williams P. Real time quantitative PCR. Genome Res 1996; 6: 986-94.
20. Takebayashi S, Ogawa T, Jung K, Muallem A, Mineta H, Fisher S, et al. Identification of new minimally lost regions on 18q in head and neck squamous cell carcinoma. Cancer Res 2000; 60: 3397-403.
21. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995; 55: 975-8.
22. Robben N, Pippas A, Moore J. The syndrome of 5-fluorouracil cardiotoxicity. Cancer 1993; 71: 493-509.
23. Akervall J, Jin Y, Wennerberg J, Zatterstrom U, Kjellén E, Mertens F, et al. Chromosomal abnormalities involving 11q13 are associated with poor prognosis in patients with squamous cell carcinoma of the head and neck. Cancer 1995; 76: 853-9.
24. Akervall J, Jin Y, Baldetorp B, Mertens F, Wennerberg J. Complex karyotypes in flow cytometrically DNA-diploid squamous cell carcinomas of the head and neck. Br J Cancer 1998; 77: 1082-8.
25. Tennvall J, Wennerberg J, Anderson H, Baldetorp B, Fernö M, Willén R. DNA analysis as a predictor of the outcome of induction chemotherapy in advanced head and neck carcinomas. Arch Otolaryngol Head Neck Surg 1993; 119: 867-70.